Topics

. @pfizer licenses exclusive global rights to @akceatx Phase II candidate AKCEA-ANGPTL3-LRx, through an agreement that could generate up to $1.5B+ for Akcea and corporate parent @ionispharma : http://ow.ly/Fulk50wEG3U pic.twitter.com/DnkirvgrM1

17:55 EDT 7 Oct 2019 | Genetic Engineering News

. licenses exclusive global rights to Phase II candidate AKCEA-ANGPTL3-LRx, through an agreement that could generate up to $1.5B+ for Akcea and corporate parent : http://ow.ly/Fulk50wEG3U 

Original Article: . @pfizer licenses exclusive global rights to @akceatx Phase II candidate AKCEA-ANGPTL3-LRx, through an agreement that could generate up to $1.5B+ for Akcea and corporate parent @ionispharma : http://ow.ly/Fulk50wEG3U pic.twitter.com/DnkirvgrM1

NEXT ARTICLE

More From BioPortfolio on ". @pfizer licenses exclusive global rights to @akceatx Phase II candidate AKCEA-ANGPTL3-LRx, through an agreement that could generate up to $1.5B+ for Akcea and corporate parent @ionispharma : http://ow.ly/Fulk50wEG3U pic.twitter.com/DnkirvgrM1"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...